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	Background	
The	UK	has	the	highest	prevalence	of	opioid	use	disorder	(OUD)	in	Europe	with	
approximately	150,000	people	currently	receiving	treatment	for	dependent	opioid	
use.	1	Since	the	1980s	a	unified	harm	minimisation	approach,	which		targets	the	high	
mortality	and	morbidity	associated	with	injected	OUD,	has	led	to	promotion	of		inhaled	
use	of	heroin	as	an	alternative	to	injection	2 
	 
Now,	a	high	prevalence	of	premature	onset	of	obstructive	airways	disease	and	
respiratory	related	deaths	within	the	opioid	use	disorder	(OUD)	population	globally	is	of	
increasing	concern.	3	This	may	be	linked		to	inhaled	opioid	use	(which	is	known	to	cause	
bronchoconstriction)	,	compounded	by	inhalation	of	tobacco,	cannabis	,	crack	cocaine	
inhalation	and	the	substances	with	which	illicit	drugs	are	mixed.	4 
Researchers	from	Liverpool	(UK)	have	published	data	from	the	largest	international	
spirometry	screening	study	to	date	of	a	cohort	receiving	treatment	for	OUD	with	a	
current	or	past	history	of	inhaled	heroin	use.	They	report	a	hitherto	under-
recognised		burden	of		respiratory	disease	in	a	relatively	young	population.	They	
diagnosed	over	half	of	753	as	having	COPD	or	Asthma-	COPD	overlap	disorder	
(ACO)	(each	group	having	fixed	airflow	obstruction,	but	differentiated	based	on	prior	
physician	diagnosis	of	asthma).	5 
	 
A	limitation	of	the	Liverpool	group’s	cross-sectional	cohort	group	is	its	use	of	almost	
entirely	spirometric	diagnostic	classification.	In	addition,	whilst	the	abnormality	in	
some	patients	was	substantial,	in	others	it	was	mild.	Interpretation	is	aided	
by	their	longitudinal	spirometric	follow	up,	successful	in	106	of	372	(28%)	originally	
diagnosed	as	having	COPD	or	ACO.	The	participants	in	this	current	study	constituted	
around	14%		of	the	original	screened	cohort	of	753	(those	without	abnormalities	at	first	
screening	were	not	followed	up).	Generalisability	of	the	findings	from	this	study	is	
compromised	by	the	high	proportion	of	participants	lost	to	follow	up.	The	authors	
were	also	limited	in	their	ability	to	adjust	adequately	or	perform	subgroup	analyses	
with	respect	to	persistence	of,	or	changes	in,		smoking	status	for	heroin,	tobacco	or	
cocaine.	So	we	know	that	participants	used	other	inhaled	substances,	but	without	a	
comparator	group,	their	contribution	cannot	be	judged.	6		The	hazards	of	spirometry	led	
diagnosis	are	apparent	in	that	around	10%	subjects	were	reclassified	as	having	asthma	
(positive	acute	reversibility)	or	normal	spirometry).	Despite	this,	the	group	overall	had	
an	accelerated	loss	of	FEV1	and	an	increase	in	symptoms,	showing	this	is	clinically	
relevant	lung	disease	contributing	to	overall	burden	of	ill	health. 
	 
Importantly,	the	Liverpool	team	also	showed	that	the	majority	of	the	follow	up	cohort	
did	engage	with	primary	care	services	and	receive	treatment	following	screening.		This	
patient	population	is	often	seen	as	highly	challenging	to	engage,	but	this	
research	disputes	this	notion.	The	research	team	have	established	significant	
engagement	from	both	healthcare	providers	and	the	participants,	with	rich	
sociodemographic	data,	including	use	of	other	inhaled	substances	(crack	cocaine,	
tobacco,	cannabis)	,		collected	alongside	high	quality	outcome	data. 
	 
How	this	advances	the	field 
For	clinicians	and	academics	alike,	the	observation	of	significant	lung	disease	burden	in	
relatively	young	people	stabilised	in	drug	treatment	settings	is	of	growing	concern.	The	
Liverpool	study	describes	early	onset,	rapidly	progressive	COPD,	but	subsequent	
engagement	with	healthcare	services	when	offered,	making	a	
compelling	argument	for	case	finding	and	early	intervention. 
	 
In	Switzerland,	the	observed	prevalence	rates	of	COPD	in	a	population	of	clinic	
attendees	were	very	similar	to	UK	settings,	despite	differing	sociocultural	patient	
demographics	and	service	delivery	models.	The	study	by	Grischott	et	al	addressed	a	
further	important	gap	in	the	literature.	Participants	who	had	screened	positive	for	
COPD	expressed	willingness	to	access	treatment.	However,	
they	often	preferred	pharmacological		treatments	over	self-management	options	and	
smoking	cessation	interventions.	7 
	 
A	higher	rate	of		hospitalisations	was	observed	in	this	current	study	than	would	be	
expected	in	such	a	young	population.	In	a	recent	large	cohort	study	of	6683	people	
undergoing	community-based	treatment	for	heroin	dependence	(London,	UK)	,	age	and	
gender	linked	reference	rates	were	used	to	quantify	excess	death	and	hospitalisations	.	
There	were	48	excess	deaths	due	to	COPD,	the	second	largest	subcategory	overall	of	
excess	deaths	in	the	OUD	population.	During	44,950	hospital	admission	years,	there	
were	an	excess	of		812	COPD	admissions.	8 
	 
Impact	on	practice 
People	with	opioid	use	disorder	(OUD)	have	high	levels	of	physical	multimorbidity	yet	
delayed	presentation	for	healthcare.	9	This	may	reduce	treatment	efficacy	for	long	term	
conditions	and	increases	treatment	burden	and	costs	(for	example	blood	borne	viruses,	
chronic	venous	ulcers).	Poor	access	to	primary	care,	leads	to	inevitable	increased	
hospitalisation	for	physical	health	problems.	OUD	treatment	settings	which	offer	co-
located	and	tailored	physical	care	for	treatment	for	Hepatitis	C		find	an	increased	uptake	
of	treatment	and	completion	rates	for	their	treatment	programmes,	a	model	which	
might	be	generalisable.	10 
	 
A	rationale	for	not	screening	people	with	OUD	for	prevalent	physical	co-morbidities	is	
that	they	'do	not	engage	with	physical	healthcare'	and	have	chaotic	‘lifestyles’.	In	reality,	
the	poor	engagement	with	healthcare	is	influenced	by	so	much	more	than	the	daily	
challenges	of	drug	seeking	behaviours.	New	symptoms	may	be	over-shadowed	in	time	
limited	consultations	where	both	patient	and	practitioners	may	be	overwhelmed	by	the	
complexity	of	mental	-physical	multimorbidity.	People	with	OUD	experience	stigma	and	
discrimination	in	routine	health	care	settings.	Poverty,	family	breakdown	and	
incarceration	lead	to	address	changes	and	loss	of	continuity	,	even	where	universal	
healthcare	is	available.	11 
This	UK	based	study	and	others	further	challenges	therapeutic	nihilism	about	proactive	
care	within	treatment		settings	for		OUD.	There	were	very	high	levels	in	engagement	
for	baseline	screening	for	COPD	and	ACO	(73%)	and	the	majority	of	participants	had	
engaged	with	some	level	of	primary	care	treatment.	The	observed	increased	
hospitalisations	in	a	relatively	young	population	would	be	of	interest	to	
commissioners.	Cost	-effective	interventions	such	as		universal	access	to	influenza	and	
pneumonia	immunisations	might	reduce	hospitalisations	associated	with	respiratory	
disease	in	this	high	risk	population	during	winter	months.	12 
	 
Future	Research 
This	study	suggests	many	of	the	criteria	for	useful	case	finding	are	met.	A	common,	high	
risk	group	with	clinically	relevant	disease	has	been	identified.	Success	in	changing	
treatment	to	improve	symptoms	has	been	demonstrated,	with	a	potential	to	change	long	
term	burden	of	ill	health.	Further	large	scale	studies	are	now	warranted	to	assess	the	
cost	effectiveness	of	such	case	finding	and	to	define	better	the	most	successful	treatment	
contexts	and	modalities.	It	is	important	healthcare	workers	understand	that	harm	
reduction	strategies	should	not	cease	with	an	end	to	injecting	drug	use,	but	need	to	
recognise	that	associated	with	smoking	opiates	and	other	drugs	too.	 
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